Natalia Dinislamovna Gazatova

Natalia Dinislamovna Gazatova

Auto-generated profile, based on publicly available information

Natalia Dinislamovna Gazatova

Immanuel Kant Baltic Federal University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Daria Shunkina (Skuratovskaia)Daria Shunkina (Skuratovskaia)
Daria Shunkina (Skuratovskaia)
AKAleksandra Komar
Aleksandra Komar
MVMaria Vulf
Maria Vulf
Hung Vu QuangHung Vu Quang
Hung Vu Quang
ESEgor Shunkin
Egor Shunkin
LLLarisa Litvinova
Larisa Litvinova
Interleukin (IL)-6 family cytokines act through a receptor complex with gp130 subunits. IL-6 is a pleiotropic cytokine that regulates inflammation and liver regeneration. Mitochondria are the first to respond to stress and adapt their dynamics in conditions of damage. In this regard, the study aimed to investigate the role of the IL-6 cytokine family (sIL-6Ra, gp130/sIL-6Rb, and IL-11) in the regulation of mitochondrial dynamics in the liver in obese patients and to assess the contribution of these cytokines to the pathogenesis of type 2 diabetes mellitus (T2DM). We studied 134 obese patients with and without T2DM and 41 healthy donors. We found that increasing the concentration of sIL-6Ra and gp130/sIL-6Rb protected against carbohydrate disorders in obese patients and prevented non-alcoholic fatty liver disease (NAFLD) progression in obese patients. An increase in plasma IL-6 levels is associated with decreased, mitochondrial transcription factor A (TFAM) protein production in liver biopsies in obese patients with and without T2DM. Replication, transcription, and division processes in liver biopsy were reduced in patients with T2DM. Inflammatory processes stimulate liver cell apoptosis in obese patients with T2DM. The increase in IL-11 levels is associated with decreased pro-apoptotic Bcl-2-associated X protein (BAX) protein production in obese patients with and without T2DM.

Verified
Journal Article
Open access
PDF file
NTNatalia Todosenko
Natalia Todosenko
OKOlga Khaziakhmatova
Olga Khaziakhmatova
VMVladimir Malashchenko
Vladimir Malashchenko
KYKristina Yurova
Kristina Yurova
MBMaria Bograya
Maria Bograya
LLLarisa Litvinova
Larisa Litvinova
Metabolic syndrome (MetS) is a precursor to the major health diseases associated with high mortality in industrialized countries: cardiovascular disease and diabetes. An important component of the pathogenesis of the metabolic syndrome is mitochondrial dysfunction, which is associated with tissue hypoxia, disruption of mitochondrial integrity, increased production of reactive oxygen species, and a decrease in ATP, leading to a chronic inflammatory state that affects tissues and organ systems. The mitochondrial AAA + protease Lon (Lonp1) has a broad spectrum of activities. In addition to its classical function (degradation of misfolded or damaged proteins), enzymatic activity (proteolysis, chaperone activity, mitochondrial DNA (mtDNA)binding) has been demonstrated. At the same time, the spectrum of Lonp1 activity extends to the regulation of cellular processes inside mitochondria, as well as outside mitochondria (nuclear localization). This mitochondrial protease with enzymatic activity may be a promising molecular target for the development of targeted therapy for MetS and its components. The aim of this review is to elucidate the role of mtDNA in the pathogenesis of metabolic syndrome and its components as a key component of mitochondrial dysfunction and to describe the promising and little-studied AAA + LonP1 protease as a potential target in metabolic disorders.

1 March 2018 in Cellular Immunology
Verified
Journal Article
Closed access
VMVladimir Vladimirovich Malashchenko
Vladimir Vladimirovich Malashchenko
MMMaxsim Evgenievich Meniailo
Maxsim Evgenievich Meniailo
VSViacheslav Anatolievich Shmarov
Viacheslav Anatolievich Shmarov
NGNatalia Dinislamovna Gazatova
Natalia Dinislamovna Gazatova
OMOlga Borisovna Melashchenko
Olga Borisovna Melashchenko
VSVictor Seledtsov
Victor Seledtsov

1 September 2017 in International Immunopharmacology
Verified
Journal Article
Closed access
MMMaksim Evgenievich Meniailo
Maksim Evgenievich Meniailo
VMVladimir Vladimirovich Malashchenko
Vladimir Vladimirovich Malashchenko
VSViacheslav Anatolievich Shmarov
Viacheslav Anatolievich Shmarov
NGNatalia Dinislamovna Gazatova
Natalia Dinislamovna Gazatova
OMOlga Borisovna Melashchenko
Olga Borisovna Melashchenko
VSVictor Seledtsov
Victor Seledtsov

22 September 2021 in Current Pharmaceutical Design
Verified
Journal Article
Open access
PDF file
Daria Shunkina (Skuratovskaia)Daria Shunkina (Skuratovskaia)
Daria Shunkina (Skuratovskaia)
MVMaria Vulf
Maria Vulf
OKOlga Khaziakhmatova
Olga Khaziakhmatova
VMVladimir Malashchenko
Vladimir Malashchenko
AKAleksandra Komar
Aleksandra Komar
LLLarisa Litvinova
Larisa Litvinova
Background: Despite the great interest and numerous studies, there is currently no unified standard describing the sequential manipulation with cells to obtain exosomes for clinical use.The use of exosomes has become an attractive alternative to cell therapy, since the flexible nature of these biological vesicles allows scientists to manipulate their composition to produce the desired exosomes carrying specific drugs, RNA and proteins. This study aimed to analyse scientific literature on the changes in the functional characteristics of exosomes, depending on the method of manipulation, potentially contributing to the development of negative effects in the treatment of diseases of inflammatory genesis. Results: The choice of isolation method affects the expressed sets of protein markers, nucleic acids and receptors on microparticles. Various surface receptors present on the exosome membrane can be engineered to target lesions. Exosomes from healthy patients help to reduce inflammation, normalize intercellular communication and have anti-fibrotic, antioxidant, and cytoprotective effects. Exosomes can change the microenvironment, but the microenvironment can also change the composition of exosomes. Conclusion: Exosomes obtained from sick patients carry markers characteristic of the corresponding disease. Such exosomes can have pro-inflammatory, pro-fibrotic, cytotoxic, and oncogenic properties, and disrupt cellular cooperation. Until now, questions regarding the dose, reactions to repeated administration, and dosage regimes have not been completely resolved.

1 October 2016 in European Cytokine Network
Verified
Journal Article
Closed access
VSVyacheslav A. Shmarov
Vyacheslav A. Shmarov
VMVladimir V. Malashchenko
Vladimir V. Malashchenko
MMMaksim E. Meniailo
Maksim E. Meniailo
NGNatalia D. Gazatova
Natalia D. Gazatova
NTNatalia Todosenko
Natalia Todosenko
VSVictor Seledtsov
Victor Seledtsov
СD3+ T lymphocytes were isolated by positive magnetic separation from the peripheral blood of healthy donors. In the absence of any additional activating stimuli, interleukin-7 (IL-7) was shown to augment the levels of T cells expressing CD25 activation marker both in СD4-positive and in CD4-negative effector memory (CD45RA-CD197-) T cell subsets, as well as in terminally differentiated (CD45RA+CD197-) Т cells, without significantly affecting the activation status of naive (CD45RA+CD197+) and central memory (CD45RA-CD197+) T cells. In addition, IL-7 noticeably enhanced the production of IL-2, interferon-γ (IFN-γ), and IL-10, but not IL-4, in T cells. The direct effects of IL-7 on T cell activation induced in vitro by MACSiBead™ particles coated with CD2, CD3, and CD28 antibodies (Abs) were also investigated. Upon cell activation, IL-7 significantly augmented the levels of CD25+ T cells in naive (CD45RA+CD197+), central memory (CD45RA-CD197+), and effector memory (CD45RA-CD197-) T-cell compartments. In addition, IL-7 facilitated activation of СD4- (but not CD4+) terminally differentiated effector (CD45RA+CD197-) Т cells. Finally, IL-7 was found to upregulate the production of IL-2, IFN-γ, IL-4, and IL-10 by activated T cells. In conclusion, we speculate that IL-7 is capable of enhancing functional T cell activity without causing significant functional inbalance between various T cell subsets.